High Neutrophil–Lymphocyte Ratio and Low Lymphocyte–Monocyte Ratio Combination after Thrombolysis Is a Potential Predictor of Poor Functional Outcome of Acute Ischemic Stroke
and Amir H. Shemirani 1,6,*
Round 1
Reviewer 1 Report
Good piece of work by Sadeghi et al. The paper is very sound and well written. I just have a minor comment to improve the introduction section by including the data of global Ischemic Stroke burden and the Rate/ratio of ischemic stroke Globally. Also, could you please discuss the Golden hour and Gold standard for the benefit of the students. Best wishes!
Author Response
Response to Reviewer 1 Comments
Comments and Suggestions for Authors
Good piece of work by Sadeghi et al. The paper is very sound and well written. I just have a minor comment to improve the introduction section by including the data of global Ischemic Stroke burden and the Rate/ratio of ischemic stroke Globally. Also, could you please discuss the Golden hour and Gold standard for the benefit of the students. Best wishes!
Accepted and amended: Many thanks to the reviewer for this kind comment. We have added some explanation to the introduction as instructed. We highlighted the changes.
Stroke is ranked the second most common cause of death and the third leading cause of death and disability in the world. There were 6.5 million deaths from stroke and 143 million disability-adjusted life-years due to stroke globally in 2019 [1].
Recent data has shown that treatment within the first hour of symptom onset produces significantly improved rates of morbidity and mortality [3]. This remarkable 60 min period from the onset of symptoms is often referred to as The Golden Hour. rt-TPA is the current gold standard for the treatment of AIS [4].
Reviewer 2 Report
The article is well written. There are still some spelling errors that should be corrected.
Author Response
Response to Reviewer 2 Comments
Comments and Suggestions for Authors
The article is well written. There are still some spelling errors that should be corrected.
Accepted and amended: We would like to thank the reviewer for his/her time and effort. We revised thoroughly our manuscript and highlighted the changes in the manuscript.
Line 23: a diagnosis
Line 25: Clinical data,
Line 54: with recombinant
Line 63: hemorrhage.
Line 84: Clinical data,
Line 92: the Trial
Line 96: A short-term
Line 97: The favorable
Line 142: The median baseline
Line 145: neurological
Table 1: Anti-diabetic
Line 187: A similar
Line 213: LMR of the
Line 217: cutoff
Line 296: are
Line 304: of the NRL
Line 305: cutoff
Line 318: patients
Line 325: a similar trend
Line 331: determines
Line 347: cutoff
Author Response File: 
Author Response.docx
